Literature DB >> 16322318

Sex steroid-producing enzymes in human breast cancer.

Takashi Suzuki1, Yasuhiro Miki, Yasuhiro Nakamura, Takuya Moriya, Kiyoshi Ito, Noriaki Ohuchi, Hironobu Sasano.   

Abstract

It is well known that sex steroids are involved in the growth of breast cancers, and the great majority of breast carcinomas express estrogen (ER), progesterone (PR), and androgen (AR) receptors. In particular, recent studies have demonstrated that estrogens and androgens are locally produced in breast carcinoma tissues, and total blockade of in situ estrogen production potentially leads to an improvement in prognosis of breast cancer patients. Therefore, it is important to obtain a better understanding of sex steroid-producing enzymes in breast carcinoma tissues. In this review, we summarize recent studies on the expression and regulation of enzymes related to intratumoral production of estrogens (aromatase, 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1), and steroid sulfatase (STS) etc) and androgens (17betaHSD5 and 5alpha-reductase) in human breast carcinoma tissues, and discuss the biological and/or clinical significance of these enzymes. The cellular localization of aromatase in breast carcinoma tissues still remains controversial. Therefore, we examined localization of aromatase mRNA in breast carcinoma tissues by laser capture microdissection/real time-polymerase chain reaction. Aromatase mRNA expression was detected in both carcinoma and intratumoral stromal cells, and the expression level of aromatase mRNA was higher in intratumoral stromal cells than in carcinoma cells in the cases examined. We also examined an association among the immunoreactivity of enzymes related to intratumoral estrogen production and ERs in breast carcinoma tissues, but no significant association was detected. Therefore, the enzymes responsible for the intratumoral production of estrogen may not always be the same among breast cancer patients, and not only aromatase but also other enzymes such as STS and 17betaHSD1 may have important therapeutic potential as targets for endocrine therapy in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322318     DOI: 10.1677/erc.1.00834

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  41 in total

1.  Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.

Authors:  Daphne Gschwantler-Kaulich; Anneliese Fink-Retter; Klaus Czerwenka; Gernot Hudelist; Axel Kaulich; Ernst Kubista; Christian F Singer
Journal:  Tumour Biol       Date:  2010-12-29

2.  Intratumoral estrogen sulfotransferase induction contributes to the anti-breast cancer effects of the dithiocarbamate derivative TM208.

Authors:  Xi-wei Ji; Guang-ping Chen; Yan Song; Ming Hua; Li-jie Wang; Liang Li; Yin Yuan; Si-yuan Wang; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2015-05-04       Impact factor: 6.150

3.  The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women.

Authors:  Kim N Danforth; A Heather Eliassen; Shelley S Tworoger; Stacey A Missmer; Robert L Barbieri; Bernard A Rosner; Graham A Colditz; Susan E Hankinson
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

4.  Lactogens and estrogens in breast cancer chemoresistance.

Authors:  Gila Idelman; Eric M Jacobson; Traci R Tuttle; Nira Ben-Jonathan
Journal:  Expert Rev Endocrinol Metab       Date:  2011-05

Review 5.  Androgens in human breast carcinoma.

Authors:  Takashi Suzuki; Yasuhiro Miki; Kiyoshi Takagi; Hisashi Hirakawa; Takuya Moriya; Noriaki Ohuchi; Hironobu Sasano
Journal:  Med Mol Morphol       Date:  2010-08-04       Impact factor: 2.309

6.  Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma.

Authors:  Kiyoshi Takagi; Takuya Moriya; Masafumi Kurosumi; Kimako Oka; Yasuhiro Miki; Akiko Ebata; Takashi Toshima; Shoji Tsunekawa; Hiroyuki Takei; Hisashi Hirakawa; Takanori Ishida; Shin-Ichi Hayashi; Junichi Kurebayashi; Hironobu Sasano; Takashi Suzuki
Journal:  Horm Cancer       Date:  2012-10-18       Impact factor: 3.869

Review 7.  Exemestane: a review of its use in postmenopausal women with breast cancer.

Authors:  Emma D Deeks; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  17β Hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma.

Authors:  Marta Szajnik; Miroslaw J Szczepanski; Esther Elishaev; Carmen Visus; Diana Lenzner; Maciej Zabel; Marta Glura; Albert B DeLeo; Theresa L Whiteside
Journal:  Gynecol Oncol       Date:  2012-08-17       Impact factor: 5.482

9.  Analyzing the regulation of metabolic pathways in human breast cancer.

Authors:  Gunnar Schramm; Eva-Maria Surmann; Stefan Wiesberg; Marcus Oswald; Gerhard Reinelt; Roland Eils; Rainer König
Journal:  BMC Med Genomics       Date:  2010-09-10       Impact factor: 3.063

10.  Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells.

Authors:  C Martínez-Campa; A González; M D Mediavilla; C Alonso-González; V Alvarez-García; E J Sánchez-Barceló; S Cos
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.